MCID: PRL009
MIFTS: 49

Prolactinoma malady

Genetic diseases, Rare diseases, Reproductive diseases, Endocrine diseases, Cancer diseases categories

Aliases & Classifications for Prolactinoma

About this section
Sources:
10Disease Ontology, 47Novoseek, 12DISEASES, 51Orphanet, 65UMLS, 36MeSH, 45NIH Rare Diseases, 24GTR, 59SNOMED-CT, 42NCIt, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet
See all sources

Aliases & Descriptions for Prolactinoma:

Name: Prolactinoma 10 47 12 51 65 36
Prolactinoma, Familial 45 24
Pituitary Adenoma, Prolactin-Secreting 10
Prolactin-Secreting Pituitary Adenoma 51
Prl-Secreting Pituitary Adenoma 51
 
Prolactinoma of Pituitary Gland 10
Pituitary Lactotrophic Adenoma 51
Familial Prolactinoma 10
Lactotroph Adenoma 51
Prloma 51


Classifications:



Characteristics (Orphanet epidemiological data):

51
prolactinoma:
Prevalence: 1-5/10000 (United Kingdom),6-9/10000 (Belgium),1-5/10000 (Switzerland),1-9/100000 (Malta); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy


External Ids:

Disease Ontology10 DOID:5394
NCIt42 C3342
MeSH36 D015175
Orphanet51 2965
ICD10 via Orphanet28 E22.1, D35.2
MESH via Orphanet37 D015175
UMLS via Orphanet66 C0033375

Summaries for Prolactinoma

About this section
NIH Rare Diseases:45 A prolactinoma is a tumor of the pituitary gland, which controls production of many hormones.  a prolactinoma causes increased levels of the hormone prolactin.  the symptoms of prolactinoma may include unusual milk production (galactorrhea) or no menstrual cycles (amenorrhea) in women or decreased sex drive in men.  most prolactinomas occur by chance (sporadically); in a small number of cases, prolactinoma may be associated with an inherited condition such as multiple endocrine neoplasia type 1 (men1) or other genetic factor. last updated: 4/5/2015

MalaCards based summary: Prolactinoma, also known as prolactinoma, familial, is related to hyperprolactinemia and fibrosarcoma. An important gene associated with Prolactinoma is AIP (Aryl Hydrocarbon Receptor Interacting Protein), and among its related pathways are Growth hormone receptor signaling and Adipogenesis. Affiliated tissues include pituitary, bone and thyroid, and related mouse phenotypes are adipose tissue and muscle.

Wikipedia:68 A prolactinoma is a benign tumor (adenoma) of the pituitary gland that produces a hormone called... more...

Related Diseases for Prolactinoma

About this section

Diseases related to Prolactinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 265)
idRelated DiseaseScoreTop Affiliating Genes
1hyperprolactinemia30.4DRD2, GH1, GNRH1, IGF1, PRL, SST
2fibrosarcoma30.2GNRH1, PRL
3diabetes insipidus30.0GNRH1, IGF1, PRL
4reproductive system disease29.9ESR1, IGF1
5multiple endocrine neoplasia 129.7MEN1, PRKAR1A, PRL, SST
6pituitary carcinoma28.6AIP, DRD2, GH1, IGF1, MEN1, POU1F1
7adenoma10.6
8pituitary tumors10.5
9pituitary adenoma10.5
10acromegaly10.4
11multiple endocrine neoplasia10.4
12pituitary adenoma, prolactin-secreting10.4
13pseudotumor cerebri10.4
14psychotic disorder10.4
15gigantism10.4
16headache10.3
17pituitary apoplexy10.3
18ainhum10.3DRD2, PRL
19pancreatic lipomatosis duodenal stenosis10.3MEN1, SST
20paroxysmal nocturnal hemoglobinuria10.3MEN1, SST
21pituitary gland disease10.3
22thyroiditis10.3
23nephrogenic adenoma of urinary bladder10.3DRD2, PRL
24testis rhabdomyosarcoma10.3IGF1, SST
25endometritis10.3GNRH1, PRL
26pleuropneumonia10.3PRL, SST
27chronic nk-cell lymphocytosis10.3GNRH1, PRL
28brill-zinsser disease10.3DRD2, PRL
29conjunctiva squamous cell carcinoma10.2SST, SSTR5
30morphine dependence10.2GNRH1, PRL
31appendiceal l-cell glucagon-like peptide producing tumor10.2IGF1, PRL
32hydrocephalus10.2
33hypothalamic neoplasm10.2
34brain cancer10.2
35central nervous system cancer10.2
36endocrine gland cancer10.2
37hypogonadism10.2
38hypothalamic disease10.2
39free sialic acid storage disorders10.2GH1, PRL
40ovarian cystadenocarcinoma10.2GNRH1, PRL
41congenital coronary artery aneurysm10.2GH1, PRL
42secondary progressive multiple sclerosis10.2MEN1, SST
43central nervous system primitive neuroectodermal neoplasm10.2IGF1, PRL
44penile disease10.2GNRH1, PRL
45pituitary dermoid and epidermoid cysts10.2GH1, SST
46lung giant cell carcinoma10.2MEN1, SST
47telangiectatic glomangioma10.2POU1F1, PRL
48gangliocytoma10.2
49gigantism advanced bone age hoarse cry10.2AIP, PRL
50duodenal disease10.2MEN1, SST

Graphical network of the top 20 diseases related to Prolactinoma:



Diseases related to prolactinoma

Symptoms for Prolactinoma

About this section

Drugs & Therapeutics for Prolactinoma

About this section

Drugs for Prolactinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DopamineapprovedPhase 4, Phase 2, Phase 3281462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
2
CabergolineapprovedPhase 4, Phase 2, Phase 34281409-90-754746
Synonyms:
(8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)Propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
81409-90-7
85329-89-1 (diphosphate)
AC-14150
AC1L1HO0
AC1Q5OQ0
BIDD:GT0775
BRD-K86882815-001-01-6
BRN 6020775
C08187
C26H37N5O2
CG-101
CHEBI:3286
 
CHEMBL1201087
CID54746
Cabaser
Cabaser (TN)
Cabaseril
Cabergolina
Cabergolina [Spanish]
Cabergoline
Cabergoline (JAN/USAN/INN)
Cabergoline [USAN:BAN:INN]
Cabergolinum
Cabergolinum [Latin]
D00987
DB00248
Dostinex
Dostinex (TN)
FCE-21336
FT-0081285
Galastop
HMS2090A09
LS-64370
MolPort-003-845-557
Sogilen
UNII-LL60K9J05T
cabergoline
3Dopamine AgonistsPhase 4, Phase 2, Phase 3476
4
SomatostatinPhase 2, Phase 314151110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
5
Bromocriptineapproved, investigationalPhase 22725614-03-331101
Synonyms:
(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman
(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione
(5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman
(5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman
(6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione
2-Bromo-alpha-ergocryptine
2-Bromo-alpha-ergokryptin
2-Bromo-alpha-ergokryptine
2-Bromoergocryptine Methanesulfonate
2-Bromoergokryptine
2-bromo-α-ergocryptine
2-bromo-α-ergokryptin
2-bromo-α-ergokryptine
22260-51-1 (mesylate (salt))
25614-03-3
AC-13601
AC1L1KXS
AC1Q2716
Alti-Bromocriptine
Apo-Bromocriptine
BIDD:GT0464
BPBio1_001131
BRD-K14496212-001-01-1
Bagren
Biomol-NT_000005
Bromergocryptine
Bromocriptin
Bromocriptina
Bromocriptina [INN-Spanish]
Bromocriptine
Bromocriptine (USAN/INN)
Bromocriptine Methanesulfonate
Bromocriptine [BAN]
Bromocriptine [USAN:BAN:INN]
 
Bromocriptine methanesulfonate
Bromocriptinum
Bromocriptinum [INN-Latin]
Bromocryptin
Bromocryptine
Bromoergocriptine
Bromoergocryptine
C06856
C32H40BrN5O5
CB-154
CCRIS 3244
CHEBI:3181
CHEMBL493
CID31101
Cycloset
D03165
DB01200
EINECS 247-128-5
Ergocryptine, 2-bromo- (8CI)
Ergoset
LS-64540
Lopac0_000171
MolPort-002-512-064
NCGC00024584-04
NCI60_001365
NSC169774
PDSP2_001500
Parlodel
Parlodel Snaptabs
Prestwick0_000121
Prestwick1_000121
Prestwick2_000121
SPBio_002101
UNII-3A64E3G5ZO
bromocriptine
nchembio873-comp18
6
Lapatinibapproved, investigational, Approved March 2007Phase 2292231277-92-2, 388082-78-8208908, 9941095
Synonyms:
1xkk
231277-92-2
388082-78-8
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
AB1004631
AC-1314
AC1L4LL4
AKOS005145766
CHEBI:49603
CHEMBL1201179
CHEMBL554
CID11557040
CID208908
D04024
D08108
DB01259
DB02584
EN002712
FMM
GSK 572016
GSK572016
GW 572016
GW 572016X
GW-2016
GW-572016
GW-572016F
GW2016
GW572016
HMS2089H10
I01-1247
 
Kinome_3684
Kinome_3685
LAPATINIB DITOSYLATE MONOHYDRATE
LS-187029
LS-187771
Lapatinib
Lapatinib (INN)
Lapatinib Ditosylate
Lapatinib [INN]
Lapatinib ditosylate
Lapatinib ditosylate (USAN)
Lapatinib tosilate hydrate
Lapatinib tosilate hydrate (JAN)
Lapatinib, Tykerb, GW572016
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
NCGC00167507-01
NSC745750
TL80090051
Tycerb
Tykerb
Tykerb (TN)
Tyverb
UNII-0VUA21238F
lapatinib
lapatinib ditosylate
nchembio866-comp20
7ClomiphenePhase 2147
8ZuclomiphenePhase 2147
9EnclomiphenePhase 2147
10CitrateNutraceuticalPhase 2784
11
Citric AcidnutraceuticalPhase 278477-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
12
Dexamethasoneapproved, investigationalPhase 1180650-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Baycadron
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
 
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone acetate
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone sodium phosphate
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamethsone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
Ozurdex
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
13Turmeric extractPhase 153
14
CurcuminPhase 1120458-37-7969516
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
C.I. Natural Yellow 3
CI Natural Yellow 3
Cucurmin
Curcuma
Curcumin
Curcumin I
Diferaloylmethane
Diferuloylmethane
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
Hydrastis
 
Indian saffron
Indian turmeric
Kacha haldi
Kurkumin [czech]
Merita earth
Natural yellow 3
Orange root
Safran D'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yo-kin
Zlut prirodni 3 [Czech]
15Dexamethasone 21-phosphatePhase 11806
16Dexamethasone acetatePhase 118061177-87-3
17BB 1101Phase 11848
18TurmericNutraceuticalPhase 160
19Insulin, Globin Zinc4069
20insulin4069

Interventional clinical trials:

(show all 14)
idNameStatusNCT IDPhase
1Cardiac Valve Complications in Prolactinomas Treated With CabergolineCompletedNCT00460616Phase 4
2Expression Profile of Somatostatin Receptors and Dopamine Receptor 2 in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vivo Response to Pasireotide and CabergolineRecruitingNCT01620138Phase 2, Phase 3
3Clomiphene in Males With Prolactinomas and Persistent HypogonadismCompletedNCT00697814Phase 2
4Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard TherapyRecruitingNCT00939523Phase 2
5Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 DiabetesRecruitingNCT02544321Phase 2
6Temozolomide in Treating Patients With Invasive Pituitary TumorsWithdrawnNCT00601289Phase 2
7Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma PatientsRecruitingNCT01344291Phase 1
8Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaTerminatedNCT01088763Phase 1
9Insulin Resistance in Women With ProlactinomaCompletedNCT00481299
10Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous SinusRecruitingNCT02536261
11Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education ToolsRecruitingNCT01775332
12Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary AdenomaRecruitingNCT00598949
13Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPARecruitingNCT00461188
14Rhinological Outcomes in Endonasal Pituitary SurgeryActive, not recruitingNCT01504399

Search NIH Clinical Center for Prolactinoma


Cochrane evidence based reviews: Prolactinoma

Genetic Tests for Prolactinoma

About this section

Genetic tests related to Prolactinoma:

id Genetic test Affiliating Genes
1 Prolactinoma, Familial24

Anatomical Context for Prolactinoma

About this section

MalaCards organs/tissues related to Prolactinoma:

33
Pituitary, Bone, Thyroid, Breast, Brain, Heart, Testes

Animal Models for Prolactinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Prolactinoma:

38 (show all 14)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053758.6DRD2, ESR1, GH1, IGF1, PRKAR1A
2MP:00053698.2BMP4, DRD2, ESR1, IGF1, MEN1, PRKAR1A
3MP:00053858.0AIP, BMP4, DRD2, ESR1, IGF1, MEN1
4MP:00053907.8BMP4, DRD2, ESR1, GNRH1, IGF1, PRKAR1A
5MP:00053817.5BMP4, DRD2, ESR1, GNRH1, MEN1, PRKAR1A
6MP:00107717.5AIP, BMP4, DRD2, ESR1, GNRH1, IGF1
7MP:00053707.2AIP, BMP4, DRD2, ESR1, GH1, GNRH1
8MP:00020067.2AIP, DRD2, ESR1, GNRH1, IGF1, MEN1
9MP:00053876.5DRD2, ESR1, GNRH1, IGF1, MEN1, POU1F1
10MP:00036316.1BMP4, DRD2, ESR1, GH1, GNRH1, IGF1
11MP:00053895.6BMP4, DRD2, ESR1, GH1, GNRH1, IGF1
12MP:00053785.5AIP, BMP4, DRD2, ESR1, GH1, GNRH1
13MP:00053795.3AIP, BMP4, DRD2, ESR1, GH1, GNRH1
14MP:00053765.0AIP, BMP4, DRD2, ESR1, GH1, GNRH1

Publications for Prolactinoma

About this section

Articles related to Prolactinoma:

(show top 50)    (show all 641)
idTitleAuthorsYear
1
Serum vaspin and adiponectin levels in patients with prolactinoma. (26415032)
2015
2
Are there any causes for increased thyroid volume in women with prolactinoma? (26067294)
2015
3
ENDOCRINOLOGY IN PREGNANCY: Management of the pregnant patient with a prolactinoma. (25805896)
2015
4
A case of pediatric atypical prolactinoma: significance of a multidisciplinary treatment approach. (25048518)
2014
5
Endoscopic transsphenoidal treatment of a prolactinoma patient with brain and optic chiasmal herniations. (24820730)
2014
6
The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. (25466526)
2014
7
Differential effects of estrogen and estrogen receptor antagonist, ICI 182 780, on the expression of calbindin-D9k in rat pituitary prolactinoma GHa88 cells. (25674214)
2014
8
The prevalence and natural history of pituitary hemorrhage in prolactinoma. (23585661)
2013
9
Preclinical Atherosclerosis in Patients with Prolactinoma. (24325995)
2013
10
Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors. (24287797)
2013
11
The expression of AIB1 correlates with cellular proliferation in human prolactinomas. (23433587)
2013
12
Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy. (23231524)
2012
13
Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-I^1 (TGF-I^1). (22700773)
2012
14
Insidious extension of pituitary prolactinoma: two can't-miss findings depicted on a 3.0-T MR system. (19453836)
2010
15
Inhibitory effects of anti-VEGF antibody on the growth and angiogenesis of estrogen-induced pituitary prolactinoma in Fischer 344 Rats: animal model of VEGF-targeted therapy for human endocrine tumors. (20514290)
2010
16
Proteomic analysis of prolactinoma cells by immuno-laser capture microdissection combined with online two-dimensional nano-scale liquid chromatography/mass spectrometry. (20205839)
2010
17
Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. (20478050)
2010
18
Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior. (20063113)
2010
19
An unusual collision tumor comprising a prolactinoma and a plasmocytoma originating from the sellar region. (18846427)
2010
20
Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. (19359408)
2009
21
Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. (19128367)
2009
22
Hyperprolactinemia and prolactinomas. (18226731)
2008
23
Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. (18559921)
2008
24
Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. (17287412)
2007
25
Metastatic prolactinoma: case report with immunohistochemical assessment for p53 and Ki-67 antigens. (16258673)
2005
26
Prevalence of osteopenia in men with prolactinoma. (15816365)
2005
27
Immunolocalization of Pit-1 in gonadotroph nuclei is indicative of the transdifferentiation of gonadotroph to lactotroph cells in prolactinomas induced by estrogen. (15221415)
2004
28
Squash smear findings of spherical amyloid in pituitary prolactinoma. A case report. (15192968)
2004
29
Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. (12161478)
2002
30
Prolactinomas: neurosurgical aspects]. (11965418)
2002
31
The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. (10931080)
2000
32
Non-random trisomies of chromosomes 5, 8 and 12 in the prolactinoma sub-type of pituitary adenomas: conventional cytogenetics and interphase FISH study. (10760821)
2000
33
Prevalence of MEN 1 in patients with prolactinoma. MEN1 Study Group of the Hospital de la Santa Creu i Sant Pau of Barcelona. (10396374)
1999
34
Prolactinoma. (9174699)
1997
35
Prolactinoma presenting in identical twins with multiple endocrine neoplasia type 1. (8846498)
1996
36
The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy. (8759184)
1996
37
Arrested puberty associated with apoplectic prolactinoma in a male adolescent. (7758013)
1995
38
Eruptive skin tags and keratoacanthomas in a patient with prolactinoma and colonic polyposis. (8075462)
1994
39
Anomalous growth hormone response to vasoactive intestinal peptide and peptide histidine methionine in patients with prolactinoma or hypothalamic hyperprolactinemia. (7991068)
1994
40
Clinical application of 11C-NMSP to the patients with pituitary adenoma other than prolactinoma]. (8345693)
1993
41
Pituitary apoplexy in a patient with prolactinoma following computerized tomography scan. (1341487)
1992
42
Enlarged adenomectomy for enclosed prolactinomas: a preliminary study of 26 cases. (2399846)
1990
43
Human pituitary somatotroph adenoma and prolactinoma: an ultrastructural and immunoelectron microscopical study. (2213957)
1990
44
Successful treatment of infertility in a man with a bromocriptine-resistant prolactinoma. (3117595)
1987
45
Pituitary-adrenocortical response to metoclopramide in patients with acromegaly and prolactinoma: a clinical evaluation of catecholamine-mediated adrenocorticotropin secretion. (3031125)
1987
46
Discordant responses of prolactinoma to two different dopamine agonists. (3742834)
1986
47
Transient intrasellar collection of air during bromocriptine treatment of a prolactinoma. (3762918)
1986
48
Subarachnoid metastases from a prolactinoma. (4080058)
1985
49
Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. (6866052)
1983
50
Reversible "hypopituitarism" and disappearance of microadenoma in a prolactinoma patient treated with bromocriptine. (6653805)
1983

Variations for Prolactinoma

About this section

Clinvar genetic disease variations for Prolactinoma:

5
id Gene Variation Type Significance SNP ID Assembly Location
1AIPNM_003977.3(AIP): c.40C> T (p.Gln14Ter)single nucleotide variantPathogenicrs104894194GRCh37Chr 11, 67250669: 67250669

Cosmic variations for Prolactinoma:

7
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1760PIK3CApituitary,NS,adenoma,PRL3
2771PIK3CApituitary,NS,adenoma,PRL3
3482HRASpituitary,NS,adenoma,PRL3
4483HRASpituitary,NS,adenoma,PRL3

Expression for genes affiliated with Prolactinoma

About this section
Search GEO for disease gene expression data for Prolactinoma.

Pathways for genes affiliated with Prolactinoma

About this section

GO Terms for genes affiliated with Prolactinoma

About this section

Cellular components related to Prolactinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular regionGO:00055767.6BMP4, GH1, GNRH1, IGF1, PRL, SST

Biological processes related to Prolactinoma according to GeneCards Suite gene sharing:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1adenohypophysis developmentGO:002198410.4DRD2, POU1F1
2JAK-STAT cascade involved in growth hormone signaling pathwayGO:006039710.3GH1, PRL
3positive regulation of insulin-like growth factor receptor signaling pathwayGO:004356810.2GH1, IGF1
4positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.2GH1, IGF1
5positive regulation of receptor internalizationGO:000209210.1DRD2, GH1
6cellular response to estradiol stimulusGO:007139210.1ESR1, SSTR5
7prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisGO:006052710.1ESR1, IGF1
8positive regulation of JAK-STAT cascadeGO:004642710.0GH1, PRL
9pituitary gland developmentGO:002198310.0BMP4, POU1F1
10regulation of multicellular organism growthGO:00400149.9IGF1, PRL
11regulation of branching involved in prostate gland morphogenesisGO:00606879.8BMP4, ESR1
12positive regulation of multicellular organism growthGO:00400189.6DRD2, GH1, POU1F1
13response to testosteroneGO:00335749.4BMP4, GNRH1
14response to estradiolGO:00323558.5BMP4, ESR1, GH1
15positive regulation of transcription from RNA polymerase II promoterGO:00459448.0BMP4, DRD2, ESR1, IGF1, MEN1, POU1F1
16negative regulation of cell proliferationGO:00082857.3BMP4, DRD2, GNRH1, IGF1, MEN1, POU1F1

Molecular functions related to Prolactinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1prolactin receptor bindingGO:000514810.1GH1, PRL
2growth factor activityGO:00080839.1BMP4, GH1, IGF1
3hormone activityGO:00051798.2GH1, GNRH1, IGF1, PRL, SST

Sources for Prolactinoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet